The US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application for topical roflumilast, 0.05%, for the treatment of mild to moderate atopic dermatitis (AD) in children ...

In this video, Robert Sidbury MD, MPH, division head of dermatology at Seattle Children’s Hospital and professor in the department of pediatrics at University of Washington School of Medicine, ...

Benjamin N. Ungar, MD, discussed characteristics of atopic dermatitis and how common AD is among children and adults in the U.S. He also talked about the diagnostic process and “the hope” to ...

PFIZER, a global biopharmaceutical company, today announced the availability of Cibinqo (abrocitinib) and Staquis (crisaborole) as new additions to the atopic dermatitis treatment spectrum in Malaysia ...

Once-daily roflumilast cream 0.05% is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 years, according to a study published online Feb. 20 in Pediatric Dermatology.

Asthma and atopic dermatitis are chronic inflammatory diseases of the airways and the skin, respectively, which affect hundreds of millions of children and adults globally. Most patients with asthma ...

Atopic dermatitis (eczema) is a chronic skin condition involving patches of dry, inflamed, and itchy skin. It can affect both children and adults. Various treatments can help manage symptoms.

Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic ...

Learn how ultrafine bubble showers can improve eczema symptoms by reducing inflammation and enhancing skin barrier proteins.

Lawrence Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the importance of shared decision-making in atopic dermatitis treatment, emphasizing ...

Once-daily roflumilast cream 0.05 percent is safe and effective for atopic dermatitis (AD) in patients ages 2 to 5 ye ...